Arvinas/ARVN

$34.72

1.25%
-
1D1W1MYTD1YMAX

About Arvinas

Arvinas, Inc. is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The Company uses its PROTAC Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC targeted protein degraders, that are designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. It has four investigational clinical-stage programs: vepdegestrant (ARV-471) for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-766 and bavdegalutamide for the treatment of men with metastatic castration-resistant prostate cancer, and ARV-102 for the treatment of patients with neurodegenerative disorders. Its product candidate, ARV-393, is designed to target the B-cell lymphoma 6, or BCL6 protein.

Ticker

ARVN

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

John Houston

Employees

445

Headquarters

New haven, United States

Arvinas Metrics

BasicAdvanced
$2.36B
Market cap
-
P/E ratio
-$6.62
EPS
1.93
Beta
-
Dividend rate
$2.36B
1.92649
$53.08
$13.57
752.66K
4.979
0.121
0.121
-28.35%
-59.97%
-36.1%
30.113
3.577
3.582
-43.61%
-24.67%
53.27%

What the Analysts think about Arvinas

Analyst Ratings

Majority rating from 20 analysts.
Buy

Price Targets

Average projection from 18 analysts.
104% upside
High $110.00
Low $49.00
$34.72
Current price
$70.83
Average price target

Arvinas Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-467.89% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$78.5M
126.88%
Net income
$-367.3M
473.91%
Profit margin
-467.89%
152.95%

Arvinas Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 99.55%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$1.54
-$1.25
-$1.18
-$2.53
-
Expected
-$1.51
-$1.65
-$1.58
-$1.27
-$1.42
Surprise
2.09%
-24.19%
-25.12%
99.55%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Arvinas stock?

Arvinas (ARVN) has a market cap of $2.36B as of April 22, 2024.

What is the P/E ratio for Arvinas stock?

The price to earnings (P/E) ratio for Arvinas (ARVN) stock is 0 as of April 22, 2024.

Does Arvinas stock pay dividends?

No, Arvinas (ARVN) stock does not pay dividends to its shareholders as of April 22, 2024.

When is the next Arvinas dividend payment date?

Arvinas (ARVN) stock does not pay dividends to its shareholders.

What is the beta indicator for Arvinas?

Arvinas (ARVN) has a beta rating of 1.93. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Arvinas stock price target?

The target price for Arvinas (ARVN) stock is $70.83, which is 104% above the current price of $34.72. This is an average based on projections from 18 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Arvinas stock

Buy or sell Arvinas stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing